



## Resource impact template

Resource impact

Published: 8 May 2024

Last updated: 8 May 2024

www.nice.org.uk

NICE has produced a <u>resource impact template</u> that incorporates the following technology appraisal guidance for COVID-19:

- Molnupiravir for treating COVID-19 (2025) NICE technology appraisal guidance 1056
- Remdesivir and tixgevimab plus cilgavimab for treating COVID-19 (2024) NICE technology appraisal guidance 971
- <u>Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19</u> (2023)
  NICE technology appraisal guidance 878